A Blood Test May Predict a Weak Vaccine Response Before the Shot

A person’s blood may contain useful clues about vaccine response before the vaccine is given. In a study of 4,089 people, researchers used a broad antibody panel and a deep-learning model to separate stronger COVID-19 vaccine responders from weaker ones.

KEY NUMBER
About 5% to 6% of healthy participants still had a weak vaccine response, showing why health category alone is an imperfect guide.

The immune system left clues before vaccination

The researchers measured antibodies that recognized 185 antigens, including targets from common viruses and bacteria as well as targets linked to autoimmune disease. Their dataset combined 2,445 healthy participants with 1,644 people affected by immune-suppressing diseases or treatments.

Several immunosuppressed groups were more likely to respond weakly, but the categories did not decide the outcome. Some immunosuppressed participants responded strongly, while a minority of healthy participants responded poorly. That distinction matters because broad labels can miss individual variation.

How the prediction worked

Higher pre-vaccine levels of antibodies to microbes including Staphylococcus aureus, respiratory syncytial virus and human respirovirus 3 were associated with stronger responses. The authors call these “sentinel antibodies,” meaning indicators of the antibody-producing immune system’s readiness, not antibodies that directly attack the vaccine target.

A deep-learning model then examined the full antibody pattern rather than relying on one marker. This is the most promising part of the result: the system combined many small signals that would be difficult to interpret separately. It also fits a wider move toward testing medical AI against real clinical data, where performance must be checked beyond a laboratory benchmark.

Why this could change vaccine follow-up

If prospective studies confirm the signal, antibody profiling might help doctors identify patients who need additional doses, closer monitoring or another protective plan. It could also improve vaccine trials by showing why participants with similar diagnoses respond differently.

The idea complements efforts to tailor vaccines and treatment to the individual. NewTqnia previously examined personalized mRNA cancer vaccines, but the current study asks a different question: whether a person’s existing immune history can help predict the response before vaccination.

What happens next

The researchers need to test the antibody profile prospectively, in new populations and with vaccines beyond COVID-19. They also need to define an accuracy threshold that would improve a real clinical decision rather than merely classify samples after the fact.

The practical takeaway is narrow but useful: the 185-target profile may reveal weak responders more precisely than a healthy-or-immunosuppressed label. Until prospective validation shows that acting on the prediction improves outcomes, it remains a research tool rather than a reason to change a vaccination plan.